e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Xenon Pharmaceuticals Inc.
< Previous
1
2
3
Next >
Xenon Reports Q1 2026 Financial Results and Provides Business Update
May 07, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon to Report Q1 2026 Financial Results on May 7, 2026
April 30, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
April 19, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon to Present at Upcoming Investor Conferences
April 15, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
April 07, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 12, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
March 10, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Proposed Public Offering
March 09, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
March 09, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
March 08, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
January 12, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
December 05, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
December 03, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
November 25, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon to Present at Upcoming Investor Conferences
November 06, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Reports Third Quarter 2025 Financial Results & Business Update
November 03, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon to Report Q3 2025 Financial Results on November 3, 2025
October 27, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
October 16, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
September 25, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 29, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Reports Second Quarter 2025 Financial Results & Business Update
August 11, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon to Report Q2 2025 Financial Results on August 11, 2025
August 04, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Joins the Russell 3000® and Russell 2000® Indexes
June 27, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.